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How to Measure Export via Bacterial Multidrug Resistance Efflux
Pumps
Jessica M. A. Blair, Laura J. V. Piddock
Antimicrobials Research Group, Institute of Microbiology and Infection, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, United
Kingdom
ABSTRACT Bacterial multidrug resistance (MDR) efflux pumps are an important mechanism of antibiotic resistance and are
required for many pathogens to cause infection. They are also being harnessed to improve microbial biotechnological processes,
including biofuel production. Therefore, scientists of many specialties must be able to accurately measure efflux activity. How-
ever, myriad methodologies have been described and the most appropriate method is not always clear. Within the scientific liter-
ature, manymethods are misused or data arising are misinterpreted. The methods for measuring efflux activity can be split into
two groups, (i) those that directly measure efflux and (ii) those that measure the intracellular accumulation of a substrate, which
is then used to infer efflux activity. Here, we review the methods for measuring efflux and explore the most recent advances in
this field, including single-cell or cell-free technologies andmass spectrometry, that are being used to provide more detailed in-
formation about efflux pump activity.
Multidrug resistance (MDR) efflux pumps are found in allbacterial species. They are protein complexes capable of
transporting substrate molecules with various sizes and proper-
ties from the inside of the bacterial cell to the extracellular space.
Bacterial efflux pumps are classified into five groups, the major
facilitator superfamily (MFS), the small MDR (SMR) family, the
multidrug and toxic compound extrusion (MATE) family, the
ATP-binding cassette (ABC) family, and the resistance-
nodulation-cell division (RND) family, which is the most clini-
cally relevant in terms of antibiotic resistance. The MFS, SMR,
MATE, and RND families all derive energy from the proton mo-
tive force, whereas the ABC transporters use direct hydrolysis of
ATP to drive transport.
Bacterial efflux pumps have been best studied for their role in
antibiotic resistance (1), but they are also fundamental to bacterial
physiology andmany are required for bacterial pathogens to cause
infection (2) and to form biofilms (e.g., see references 3 and 4). In
addition, export of substrates via efflux pumps is being harnessed
to improve biotechnological processes (5–7). The myriad roles of
these proteins mean that microbiologists of many specialties
working on bacteria of all species research efflux pumps. There-
fore, it is necessary to be able to quantify the activity of efflux
pumps to understand their contribution to biological processes
and to assess the validity of potential therapeutics such as efflux
inhibitors.
When studying the efflux of antimicrobial substrates, it has
been commonplace to use drug susceptibility measurements
(such as the MIC) to reveal differences in drug efflux activity. The
reason for using this method is that a bacterium with greater ex-
pression of an efflux pump will be less susceptible to various an-
timicrobials than its comparator with lower efflux pump expres-
sion. Two approaches have been typically taken. The first is a
comparison of MICs obtained for isogenic laboratory strains in
which a mutant has had a putative efflux gene inactivated or de-
leted. If the gene codes for an efflux pump that exports the drugs
tested, the MICs are lower for the mutant, as higher concentra-
tions of the drug are retained within the bacterium. In the pres-
ence of an influx inhibitor, the MICs are reduced for the parental
strain but not for themutant. The second is a comparison ofMICs
obtained in the presence and absence of inhibitors of drug efflux
for a reference strain with those obtained for collections of clinical
or veterinary isolates of bacteria. Those isolates with increased
drug susceptibility in the presence of an efflux inhibitor are pre-
sumed to overexpress one or more efflux pumps. However, this
approach has limited sensitivity and utility, as only large changes
in efflux activity will be detected in this way. The fold changes in
MICs also rarely correlate exactly with those obtained in experi-
ments that determine efflux activity directly. Furthermore, the
long time scale of susceptibility determination experiments (~18
to 24 h)means that subtle differencesmay bemissed. Therefore, it
is hard to be confident that the differences in the MICs are due to
efflux; this is particularly true for studies comparing groups of
isolates. Occasionally, disc susceptibility measurements are car-
ried out instead of MIC determinations; as there are inherent dif-
ficulties in carrying out these experiments for certain species, e.g.,
Pseudomonas aeruginosa; data arising from this approach are even
more unreliable. Therefore, direct ways of assessing efflux activity
are necessary.
There are myriad methodologies described in the literature to
measure the activity of efflux pumps in bacterial cells. Most use a
molecule that is a substrate of the efflux pumpunder investigation
andwhose relative concentration can be easily detected, for exam-
ple, by measuring fluorescence. Essentially, the methods can be
split into two categories, (i) those that directly measure efflux, i.e.,
how much of a substrate is pumped out, and (ii) those that mea-
sure how much of a substrate molecule accumulates inside the
cell, the level of which is then used to infer efflux activity indi-
rectly.
Both types of method typically use dyes that have differential
fluorescence when intra- or extracellular (Tables 1 and 2). Several
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substrates are used for these assays, including dyes that intercalate
with DNA, but most commonly, dyes such as Hoechst H33342 or
ethidium bromide are used. These fluoresce only when bound to
DNA (8). Therefore, the level of fluorescence can be used to de-
termine the relative intracellular concentration of the dye at any
time point.
DIRECT MEASUREMENT OF EFFLUX
The principle of methods that measure efflux is that cells are pre-
loaded with high concentrations of the substrate being measured,
usually in the presence of an efflux inhibitor that inhibits the
pump’s source of energy (e.g., carbonyl cyanidem-chlorophenyl-
hydrazone, which dissipates the proton motive force, or or-
thovanadate, which inhibits transport via pumps that use ATP).
This means that the substrate accumulates within the cell to a
maximum level prior to the start of the assay. The cells are then
washed to remove any extracellular substrate and inhibitor mole-
cules remaining in the medium. The fluorescence of the cells is
then measured. The initial fluorescence value is high because the
cells have accumulated dye that they are unable to pump out. The
cells are then reenergized, e.g., by the addition of glucose, allowing
efflux to restart and the dye is effluxed out of the cells. Efflux is
directly measured by recording the change in fluorescence over
time as the dye is pumped out of the cells. The rate of efflux in
different strains can be compared; for example, a strain of Salmo-
nella enterica serovar Typhimurium lacking the AcrB efflux pump
is unable to efflux ethidiumbromide out of the cell as quickly as its
isogenic wild-type parental strain (Fig. 1).
Ethidium bromide is a common substrate for these assays; it is
a DNA-intercalating agent that fluoresces only when bound to
DNA (8). Therefore, fluorescence is higher when intracellular
thanwhen extracellular, and this is used tomeasure the amount of
accumulation (e.g., see references 9 to 10). Similar data can be
obtained by using lipophilic dyes such as Nile Red and 1,2=-
dinaphthylamine (12, 13). These dyes remain largely periplasmic
and bind to membrane phospholipids, where they fluoresce more
strongly than when in aqueous solution. Again, these dyes are
more fluorescent when intracellular than when extracellular. Of
these dyes, 1,2=-dinaphthylamine is currently the most sensitive
and has the greatest signal-to-noise ratio, as its peak fluorescence
TABLE 1 Substrates commonly used to measure direct efflux
Substrate Details Advantage(s) Disadvantage(s) Reference(s)
Ethidium bromide DNA-intercalating dye; fluoresces
when bound to DNA;
excitation wavelength, 530 nm;
emission wavelength, 600 nm
Well-validated substrate of many
efflux pumps such as the RND
pump AcrB
Concentrates in cytoplasm, so efflux is
slow because there must be a
dissociation step and probably
more than one efflux event; likely to
underestimate efflux level
9, 41
Nile Red Periplasmic; lipophilic dye that
binds to membrane
phospholipids; fluoresces
weakly in aqueous solutions
but strongly fluorescent in
nonpolar environments such as
the membrane; excitation
wavelength, 552 nm; emission
wavelength, 636 nm; assay uses
stationary-phase cells
Periplasmic, so good for
studying RND efflux pumps
such as AcrB; long maximum
emission wavelength (636 nm)
means that there is less of a
problem with interference
when measuring competition
with other substrates; better
signal-to-noise ratio than
ethidium bromide; efflux is
more rapid than cytoplasmic
dyes; can be used to test
whether compounds are efflux
substrates by measuring
competition with Nile Red
Does not work well in nonfermenting
bacteria such as Pseudomonas spp.;
assay optimized for study of
AcrAB-TolC
12
1,2=-Dinaphthylamine Periplasmic; lipophilic dye that
fluoresces weakly in aqueous
solutions but strongly in
nonpolar environments such as
the membrane; more lipophilic
than Nile Red, so ideal for
studying RND efflux pumps
because phenylalanines are
important for substrate
interaction in binding pocket;
excitation wavelength, 370 nm;
emission wavelength, 810 nm
Most sensitive; can be used to
distinguish between efflux
rates of AcrB proteins with
SNPs;a well retained in
membrane while bacteria are
in deenergized state; capable
of emission in near-infrared
region of spectrum, where
cellular autofluorescence is
low
Does not work well in nonfermenting
bacteria such as Pseudomonas spp.
13




450 nm; emission wavelength,
600 nm
Very expensive 10, 42
a SNPs, single-nucleotide polymorphisms.
Perspective
















is far from the region of the spectrum where cellular autofluores-
cence is detected. Nile Red and 1,2=-dinaphthylamine are partic-
ularly well suited to the measurement of efflux through RND ef-
flux pumps. This is partly because of their periplasmic nature, as
RND efflux pumps collect their substrates from the periplasmic
space and outer leaflet of the inner membrane. This is an advan-
tage over cytoplasmic dyes such as ethidium bromide, where ef-
flux is slower; this is because the dye must first dissociate from the
DNA. Efflux is probably a two-step process involving transport
from the cytoplasm to the periplasm before export from the cell;
this could lead to underestimation of the level of efflux. 1,2=-
dinaphthylamine is more lipophilic than Nile Red and, because of
the interaction with the phenylalanine-rich substrate binding
pocket, is particularly good for studying RND efflux pumps (13).
Another consideration when choosing a substrate is whether the
results need to be interpreted in context with the protein struc-
ture. For this purpose, there are advantages to using a drug or dye
for which the exact binding position within the pump is known.
For example, doxorubicin has been cocrystallized with AcrB and
therefore its binding location is known. This allows the effects of
single-point mutations on the efflux level to be interpreted at the
level of individual amino acid residues (e.g., see reference 10).
A major benefit of measuring efflux directly is that it can be
used to obtain kinetic information about substrate export. More
specifically, these assays can be used with a dye in combination
with a molecule or drug thought to be a substrate or inhibitor of
the efflux pump to determine whether there is competition for
efflux. This approach has been used to infer whether a particular
molecule is a substrate of a given efflux pump and even to which
part of the efflux pump it binds (10, 14, 15). In addition, the
sensitivity of this approach means that it can be used to screen for
molecules that inhibit efflux and could be potential novel thera-
peutics (16–19).
METHODS FOR MEASURING INTRACELLULAR
ACCUMULATION OF AN EFFLUX PUMP SUBSTRATE
Manymethodsmeasure the accumulation of a substrate molecule
inside the bacterial cell to infer the level of efflux (examples of
commonly used substrates are shown in Table 2). The premise is
that the lower the level of efflux, the higher the concentration of
substrate accumulated within the bacterial cell. Historically, this
was carried out by using radiolabeled substrates including antibi-
otics, and the level of radioactivity was used to determine the
amount of accumulated substrate (22–25). Nowadays, it is far
more common to use fluorescent substrates or dyes for this pur-
pose. This is preferable, as the use of radioactivity is avoided. Flu-
orescence is not only easier to quantify, it allows easy scaling up of
assays to a 96- or 384-well format, but it is also cheaper and easier
to use and dispose of than radiochemicals. Common dyes include
the DNA intercalation agents ethidium bromide and Hoechst
H33342 (20, 21). These dyes fluoresce when bound to DNA and
therefore have higher fluorescence when intracellular. A benefit of
accumulation assays is that it is also possible to measure the accu-
mulation of clinically relevant drugs such as the fluoroquinolones,
which are naturally fluorescent (see discussion below).
At the beginning of accumulation experiments, the bacterial
cells have no dye or drug inside them; an initial fluorescence read-
ing is taken, anddye is then added. The fluorescence increases over
time as the dye accumulates inside the cells and reaches a steady
state (Fig. 2). In an efflux-deficient strain (e.g., a strain fromwhich
an efflux pump gene has been deleted) the steady-state level of
TABLE 2 Substrates commonly used to measure accumulation
Substrate(s) Details Advantages Disadvantages References
Hoechst H33342 DNA-intercalating dye; fluoresces when
bound to DNA; excitation
wavelength, 355 nm; emission
wavelength, 460 nm
Easy and quick to use, cheap,
and easily adapted for
high throughput
20, 21
Ethidium bromide DNA-intercalating dye; fluoresces when
bound to DNA; excitation
wavelength, 530 nm; emission
wavelength, 600 nm
Easy and quick to use, cheap,






Naturally fluorescent, but fluorescence
is the same whether intracellular or
extracellular; therefore, the assay is
done differently; the drug is allowed
to accumulate inside cells, cells are
washed and then lysed, and the
amount of drug in solution is
measured by fluorescence and related
to dry cell weight to estimate the
amount of drug inside each cell
Arguably more clinically





at timed intervals rather than
real-time kinetics, but many
time points can be taken
30, 33
FIG 1 Direct measurement of ethidium bromide efflux (40) over time by
Salmonella Typhimurium SL1344 (blue) and an isogenic acrBmutant (red).
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accumulation is higher than in an efflux-proficient strain (e.g., the
wild type) because it is not able to pump the dye out of the cell as
effectively. The relative fluorescence is used to compare levels of
efflux between strains.
Measuring accumulation is most useful for comparing iso-
genic strains or highly related clinical isolates. For example, it has
been used successfully in many species to measure changes in ef-
flux/accumulation when genes coding for efflux pumps or their
regulators are deleted or overexpressed in isogenic strains (e.g., see
references 26 to 29). This method can also be adapted for many
bacterial species, including nonfermenting bacteria that cannot
metabolize glucose and therefore the real-time efflux assays de-
scribed above are unsuitable (21, 26). While much of the discus-
sion in this article has focused on pumps, such as the RND family,
that use the proton motive force to power transport, measure-
ments of drug accumulation can also be used to assess the activity
of pumps that use alternative energy sources as long as the dyes or
drugs selected for the assay are substrates of the pumps of interest.
For example, accumulation assays have been used to assess the
activity of members of the ABC family of pumps that use the
hydrolysis of ATP to drive efflux (27–29).
However, accumulation is a less sensitive method than direct
measurement of efflux and provides only indirect evidence of a
change in efflux. This is because the amount of substrate that
accumulates inside cells is also affected by other phenotypic attri-
butes, including the rate of influx (the rate at which the dye enters
the cell). Therefore, accumulation encompasses efflux activity and
the contribution of influx to the overall level of substrate accumu-
lation. This makes this method less well suited to assessing differ-
ences in efflux between nonisogenic strains, such as in collections
of clinical isolates. This is because such isolates may have very
different outer membrane permeabilities, causing different rates
of substrate influx that will confound the quantification of efflux.
For the same reason, data from accumulation assays cannot be
used to infer efflux kinetics if the rate of substrate influx is not
known. Therefore, in many cases, only the steady-state value is
useful.
Accumulation methods can also be used to infer the level of
efflux of substrates that do not have differential fluorescence
intra- and extracellularly. These include many clinically relevant
drugs, such as the fluoroquinolones or tetracyclines (e.g., see ref-
erences 22, 28, 30, and 31). In this case, the substrate is allowed to
accumulate intracellularly. Samples are taken, and temperature
and pH are carefully controlled during the washing and lysing
stages to prevent efflux restarting. Cells are thenwashed and lysed.
The amount of molecule/drug present is then measured by fluo-
rescence or absorbance, and the concentrationwithin the bacterial
cells is calculated as the number of milligrams per unit of dry
weight of cells, the total cellular protein, or the number of cells
present before lysis. Methods have been developed for use in var-
ious bacterial species and using many different drugs (e.g., see
reference 30). An alternative method to measure accumulation of
nonfluorescent substrates is to use radioactive analogs, and exam-
ples have been described for many drugs and bacterial species,
including quinolones (32, 33, 34), tetracyclines (31), chloram-
phenicol (22), -lactams (22), and rifampin (23).
One benefit of measuring accumulation is that it can be easily
adapted for use with single-cell methods or those using more so-
phisticated detection techniques such as mass spectrometry (see
below).
RECENT DEVELOPMENTS IN EFFLUX MEASURMENT
Recently, methods have been described to assess efflux activity of
bacteria with greater resolution, in single cells, in cell-free systems,
and using a greater range of natural and synthetic substrates.
The accumulation of fluorescent dye in single cells of a bacte-
rial population can be measured by flow cytometry (e.g., see ref-
erences 9 and 35). This technique allows the fluorescence from
tens of thousands of individual cells frommultiple populations to
bemeasured. The benefit of this advancement is that the variation
in efflux activity between cells in a population can be measured
(Fig. 3) (9, 35). This has shown that the accumulation level, and
therefore probably the efflux level, is not the same in all cells but
varies within a population. This could be very important when
considering the role of efflux in the emergence of resistance in vivo
in the clinical setting. This variation in the level of dye accumula-
tion across a population has also been described in eukaryotic cell
populations (43).
One application of measuring efflux or accumulation is to
screen for molecules that can inhibit efflux as potential future
therapeutics. However, screening of natural products or complex
FIG 2 Measurement of Hoechst H33342 dye accumulation (data from ref-
erence 40) in Salmonella Typhimurium SL1344 (blue) and an isogenic acrB
mutant (red).
FIG 3 Ethidium bromide accumulation in an isogenic population of S. en-
terica showing variation in fluorescence throughout the population (data from
reference 35).
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mixtures for efflux inhibitory activity can be problematic, as they
can contain molecules that cause optical interference when used
with fluorescence-basedmethods.Onemethod to circumvent this
problem is to use quantitative mass spectrometry to measure the
concentration to which a substrate has accumulated within cells
by measuring the depletion of the substrate from spent liquid
medium. For example, Brown and colleagues (36) have used high-
performance liquid chromatography electrospray ionization-
mass spectrometry to measure ethidium bromide uptake with the
purpose of assessing efflux inhibition in Staphylococcus aureus by a
crude plant extract and pure flavonoids. Many of the methods for
measuring efflux or accumulation rely on the drugs being either
fluorescent or radioactive so that their concentration can be mea-
sured. However, mass spectrometry-based methods of measuring
drug accumulation are a major improvement because they can be
used to measure the concentration of any substrate, including
drugs (36).
All of the assays discussed thus far measure the efflux or accu-
mulation of a substrate by efflux pumps in the context of the
whole bacterial cell, where many other factors could influence the
assay outcomes. Recently, an assay has been developed in which a
tripartite RND efflux pump from Pseudomonas aeruginosa can be
reconstituted by incorporating the inner and outer membrane
components into separate proteoliposomes (37, 39). Assembly of
the tripartite system and subsequent efflux by a specific pump can
then be detected. Previously, only the inner membrane compo-
nents had been incorporated into single proteoliposomes (e.g., see
reference 38). This innovation has allowed conclusions about
complex assembly. However, in the future, this method could be
used to directly assess the impact of single-base-pairmutations on
pumpassemblywith themajor benefit of not being confounded or
masked by other cellular functions. However, at present, the assay
is only qualitative because of variability in the efficiency of recon-
stitution of the assembled pump and also in the reproducibility of
the procedure.
CONCLUSION
There are myriad methods available to assess efflux activity in
bacterial cells, but they have differing levels of sensitivity and cau-
tion should be applied so that the method chosen is appropriate
for the scientific question posed. When comparing isogenic mu-
tants, accumulation of a fluorescent substrate is valid but this
method is unsuitable for the comparison of phenotypically varied
groups or collections of bacterial isolates because other physiolog-
ical differences, such as differences in membrane permeability al-
tering dye influx rates, could confound conclusions. Direct mea-
surement of efflux is more sensitive than measurement of dye
accumulation, provides more information, and is the only valid
way to make kinetic measurements of efflux. Selection of the ap-
propriate methodology is vital to draw sound conclusions about
efflux activity.
FUNDING INFORMATION
This research received no specific grant from any funding agency in the
public, commercial, or not-for-profit sectors. JMAB is a BBSRC David
Phillips Fellow BB/M02623X/1.
REFERENCES
1. Blair JM, Richmond GE, Piddock LJ. 2014. Multidrug efflux pumps in
Gram-negative bacteria and their role in antibiotic resistance. Future Mi-
crobiol 9:1165–1177. http://dx.doi.org/10.2217/fmb.14.66.
2. Piddock LJ. 2006. Multidrug-resistance efflux pumps—not just for resis-
tance. Nat Rev Microbiol 4:629 – 636. http://dx.doi.org/10.1038/
nrmicro1464.
3. Baugh S, Ekanayaka AS, Piddock LJ, Webber MA. 2012. Loss of or
inhibition of all multidrug resistance efflux pumps of Salmonella enterica
serovar Typhimurium results in impaired ability to form a biofilm. J An-
timicrob Chemother 67:2409 –2417. http://dx.doi.org/10.1093/jac/
dks228.
4. Kvist M, Hancock V, Klemm P. 2008. Inactivation of efflux pumps
abolishes bacterial biofilm formation. Appl Environ Microbiol 74:
7376–7382. http://dx.doi.org/10.1128/AEM.01310-08.
5. Mingardon F, Clement C, Hirano K, Nhan M, Luning EG, Chanal A,
Mukhopadhyay A. 2015. Improving olefin tolerance and production in E.
coli using native and evolved AcrB. Biotechnol Bioeng 112:879–888.
http://dx.doi.org/10.1002/bit.25511.
6. Fisher MA, Boyarskiy S, Yamada MR, Kong N, Bauer S, Tullman-Ercek
D. 2014. Enhancing tolerance to short-chain alcohols by engineering the
Escherichia coli AcrB efflux pump to secrete the non-native substrate
n-butanol. ACS Synth Biol 3:30 – 40. http://dx.doi.org/10.1021/
sb400065q.
7. Yang J, Xiong Z-Q, Song S-J, Wang J-F, Lv H-J, Wang Y. 2015.
Improving heterologous polyketide production in Escherichia coli by
transporter engineering. ApplMicrobiol Biotechnol 99:8691–8700 http://
dx.doi.org/10.1007/s00253-015-6718-7:1-10.
8. Olmsted J, Kearns DR. 1977. Mechanism of ethidium bromide fluores-
cence enhancement on binding to nucleic acids. Biochemistry 16:
3647–3654. http://dx.doi.org/10.1021/bi00635a022.
9. Paixão L, Rodrigues L, Couto I, Martins M, Fernandes P, De Carvalho
CC, Monteiro GA, Sansonetty F, Amaral L, Viveiros M. 2009. Fluoro-
metric determination of ethidium bromide efflux kinetics in Escherichia
coli. J Biol Eng 3:18. http://dx.doi.org/10.1186/1754-1611-3-18.
10. Blair JM, Bavro VN, Ricci V, Modi N, Cacciotto P, Kleinekatho¨fer U,
Ruggerone P, Vargiu AV, Baylay AJ, Smith HE, Brandon Y, Galloway
D, Piddock LJ. 2015. AcrB drug-binding pocket substitution confers clin-
ically relevant resistance and altered substrate specificity. Proc Natl Acad
Sci U S A 112:3511–3516. http://dx.doi.org/10.1073/pnas.1419939112.
11. Reference deleted.
12. Bohnert JA, Karamian B, Nikaido H. 2010. Optimized Nile Red efflux
assay of AcrAB-TolCmultidrug efflux system shows competition between
substrates. Antimicrob Agents Chemother 54:3770 –3775. http://
dx.doi.org/10.1128/AAC.00620-10.
13. Bohnert JA, Schuster S, Szymaniak-Vits M, Kern WV. 2011. Determi-
nation of real-time efflux phenotypes in Escherichia coli AcrB binding
pocket phenylalanine mutants using a 1,2=-dinaphthylamine efflux assay.
PLoS One 6:e21196. http://dx.doi.org/10.1371/journal.pone.0021196.
14. Iyer R, Erwin AL. 2015. Direct measurement of efflux in Pseudomonas
aeruginosa using an environment-sensitive fluorescent dye. ResMicrobiol
166:516–524. http://dx.doi.org/10.1016/j.resmic.2015.06.006.
15. Iyer R, Ferrari A, Rijnbrand R, Erwin AL. 2015. A fluorescent microplate
assay quantifies bacterial efflux and demonstrates two distinct compound
binding sites in AcrB. Antimicrob Agents Chemother 59:2388–2397.
http://dx.doi.org/10.1128/AAC.05112-14.
16. Tegos G, Stermitz FR, Lomovskaya O, Lewis K. 2002. Multidrug pump
inhibitors uncover remarkable activity of plant antimicrobials. Antimi-
crob Agents Chemother 46:3133–3141. http://dx.doi.org/10.1128/
AAC.46.10.3133-3141.2002.
17. Lechner D, Gibbons S, Bucar F. 2008. Plant phenolic compounds as
ethidium bromide efflux inhibitors in Mycobacterium smegmatis. J Anti-
microb Chemother 62:345–348. http://dx.doi.org/10.1093/jac/dkn178.
18. Pereda-Miranda R, Kaatz GW, Gibbons S. 2006. Polyacylated oligosac-
charides from medicinal Mexican morning glory species as antibacterials
and inhibitors ofmultidrug resistance in Staphylococcus aureus. J Nat Prod
69:406–409. http://dx.doi.org/10.1021/np050227d.
19. Ettefagh KA, Burns JT, Junio HA, Kaatz GW, Cech NB. 2011. Gold-
enseal (Hydrastis canadensis L.) extracts synergistically enhance the anti-
bacterial activity of berberine via efflux pump inhibition. Planta Med 77:
835–840. http://dx.doi.org/10.1055/s-0030-1250606.
20. Coldham NG, Webber M, Woodward MJ, Piddock LJ. 2010. A 96-well
plate fluorescence assay for assessment of cellular permeability and active
efflux in Salmonella enterica serovar Typhimurium and Escherichia coli. J
Antimicrob Chemother 65:1655–1663. http://dx.doi.org/10.1093/jac/
dkq169.
21. Richmond GE, Chua KL, Piddock LJ. 2013. Efflux in Acinetobacter bau-
Perspective
















mannii can be determined by measuring accumulation of H33342 (bis-
benzimide). J Antimicrob Chemother 68:1594–1600. http://dx.doi.org/
10.1093/jac/dkt052.
22. Mortimer PG, Piddock LJ. 1993. The accumulation of five antibacterial
agents in porin-deficient mutants of Escherichia coli. J Antimicrob Che-
mother 32:195–213. http://dx.doi.org/10.1093/jac/32.2.195.
23. Williams KJ, Piddock LJ. 1998. Accumulation of rifampicin by Esche-
richia coli and Staphylococcus aureus. J Antimicrob Chemother 42:
597–603. http://dx.doi.org/10.1093/jac/42.5.597.
24. Rosenberg EY, Ma D, Nikaido H. 2000. AcrD of Escherichia coli is an
aminoglycoside efflux pump. J Bacteriol 182:1754 –1756. http://
dx.doi.org/10.1128/JB.182.6.1754-1756.2000.
25. Kobayashi N, Nishino K, Yamaguchi A. 2001. Novel macrolide-specific
ABC-type efflux transporter inEscherichia coli. J Bacteriol 183:5639–5644.
http://dx.doi.org/10.1128/JB.183.19.5639-5644.2001.
26. Morita Y, Komori Y, Mima T, Kuroda T, Mizushima T, Tsuchiya T.
2001. Construction of a series of mutants lacking all of the fourmajormex
operons formultidrug efflux pumps or possessing each one of the operons
from Pseudomonas aeruginosa PAO1:MexCD-OprJ is an inducible pump.
FEMS Microbiol Lett 202:139–143. http://dx.doi.org/10.1111/j.1574
-6968.2001.tb10794.x.
27. Al-Hamad A, Upton M, Burnie J. 2009. Molecular cloning and charac-
terization of SmrA, a novel ABCmultidrug efflux pump from Stenotroph-
omonas maltophilia. J Antimicrob Chemother 64:731–734. http://
dx.doi.org/10.1093/jac/dkp271.
28. Piddock LJ, JohnsonMM. 2002. Accumulation of 10 fluoroquinolones by
wild-type or efflux mutant Streptococcus pneumoniae. Antimicrob Agents
Chemother 46:813– 820. http://dx.doi.org/10.1128/AAC.46.3.813
-820.2002.
29. GarveyMI, Piddock LJ. 2008. The efflux pump inhibitor reserpine selects
multidrug-resistant Streptococcus pneumoniae strains that overexpress the
ABC transporters PatA and PatB. Antimicrob Agents Chemother 52:
1677–1685. http://dx.doi.org/10.1128/AAC.01644-07.
30. Piddock LJ, Jin YF, Ricci V, Asuquo AE. 1999. Quinolone accumulation
by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. J
Antimicrob Chemother 43:61–70. http://dx.doi.org/10.1093/jac/43.1.61.
31. Shales SW, Chopra I, Ball PR. 1980. Evidence for more than one mech-
anism of plasmid-determined tetracycline resistance in Escherichia coli. J
Gen Microbiol 121:221–229. http://dx.doi.org/10.1099/00221287-121-1
-221.
32. Diver JM, Piddock LJ, Wise R. 1990. The accumulation of five quinolone
antibacterial agents by Escherichia coli. J Antimicrob Chemother 25:
319–333. http://dx.doi.org/10.1093/jac/25.3.319.
33. Mortimer PG, Piddock LJ. 1991. A comparison of methods used for
measuring the accumulation of quinolones by Enterobacteriaceae, Pseu-
domonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother
28:639–653. http://dx.doi.org/10.1093/jac/28.5.639.
34. Pumbwe L, Piddock LJ. 2000. Two efflux systems expressed simultane-
ously in multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents
Chemother 44:2861–2864. http://dx.doi.org/10.1128/AAC.44.10.2861
-2864.2000.
35. Sánchez-Romero MA, Casadesús J. 2014. Contribution of phenotypic
heterogeneity to adaptive antibiotic resistance. Proc Natl Acad Sci U S A
111:355–360. http://dx.doi.org/10.1073/pnas.1316084111.
36. Brown AR, Ettefagh KA, Todd D, Cole PS, Egan JM, Foil DH, Graf TN,
Schindler BD, Kaatz GW, Cech NB. 2015. A mass spectrometry-based
assay for improved quantitative measurements of efflux pump inhibition.
PLoS One 10:e0124814. http://dx.doi.org/10.1371/journal.pone.0124814.
37. Verchère A, Dezi M, Adrien V, Broutin I, Picard M. 2015. In vitro
transport activity of the fully assembled MexAB-OprM efflux pump from
Pseudomonas aeruginosa. Nat Commun 6:6890. http://dx.doi.org/
10.1038/ncomms7890.
38. Aires JR, Nikaido H. 2005. Aminoglycosides are captured from both
periplasm and cytoplasm by the AcrD multidrug efflux transporter of
Escherichia coli. J Bacteriol 187:1923–1929. http://dx.doi.org/10.1128/
JB.187.6.1923-1929.2005.
39. Ntsogo Enguéné VY, Verchère A, Phan G, Broutin I, Picard M. 2015.
Catch me if you can: a biotinylated proteoliposome affinity assay for the
investigation of assembly of the MexA-MexB-OprM efflux pump from
Pseudomonas aeruginosa. Front Microbiol 6:541. http://dx.doi.org/
10.3389/fmicb.2015.00541.
40. Smith HE, Blair JM. 2014. Redundancy in the periplasmic adaptor pro-
teins AcrA and AcrE provides resilience and an ability to export substrates
of multidrug efflux. J Antimicrob Chemother 69:982–987. http://
dx.doi.org/10.1093/jac/dkt481.
41. Viveiros M, Martins A, Paixão L, Rodrigues L, Martins M, Couto I,
Fähnrich E, KernWV, Amaral L. 2008. Demonstration of intrinsic efflux
activity of Escherichia coli K-12 AG100 by an automated ethidium bro-
mide method. Int J Antimicrob Agents 31:458–462. http://dx.doi.org/
10.1016/j.ijantimicag.2007.12.015.
42. Nishino K, Yamaguchi A. 2001. Overexpression of the response regulator
evgA of the two-component signal transduction system modulates multi-
drug resistance conferred bymultidrug resistance transporters. J Bacteriol
183:1455–1458. http://dx.doi.org/10.1128/JB.183.4.1455-1458.2001.
43. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel
U, Goodell MA, Brenner MK. 2004. A distinct “side population” of cells
with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci
U S A 101:14228–14233. http://dx.doi.org/10.1073/pnas.0400067101.
Perspective








ber 6, 2016 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
